Xuezhikang, an Extract of Cholestin, Protects Endothelial Function Through Antiinflammatory and Lipid-lowering Mechanisms in Patients with Coronary Heart Disease
Overview
Authors
Affiliations
Background: Endothelial dysfunction is associated with inflammation and postprandial hypertriglyceridemia. Xuezhikang, an extract of Cholestin, a dietary supplement, has lipid-modulating and antiinflammatory effects. We explored the effects of xuezhikang on endothelial function and high-sensitivity C-reactive protein (hs-CRP) in patients with coronary heart disease (CHD).
Methods And Results: We prospectively randomized 50 CHD patients to xuezhikang 1200 mg/d or placebo for 6 weeks. Fasting hs-CRP concentrations, flow-mediated vasodilation (FMD) at 0 and 4 hours, and lipid parameters at 0, 2, 4, and 6 hours were monitored after a high-fat meal (800 calories; 50 g fat) in all patients. All patients underwent a high-fat meal test at the beginning of the study and after 6 weeks of treatment. Postprandial FMD was significantly worse at 4 hours after a high-fat meal (P<0.05), and this was associated with the area under the triglyceride curve (TG-AUC) (r=0.345, P<0.01). After 6 weeks of xuezhikang, fasting hs-CRP levels and TG-AUC (P<0.001 for each) decreased. Furthermore, preprandial and postprandial FMD significantly improved (P<0.001). There were no significant changes in serum lipids and FMD in the placebo arm. In multivariable regression analysis, changes in TG-AUC and fasting hs-CRP levels were predictive of improvement in preprandial FMD (P<0.05).
Conclusions: Xuezhikang effectively improved preprandial and postprandial endothelial function through its potent antiinflammatory and lipid-lowering effects.
Jian X, Yuntao L, Zhihao L, Zhen Z, Dawei W, Qing L J Tradit Chin Med. 2024; 44(6):1082-1090.
PMID: 39617693 PMC: 11589558. DOI: 10.19852/j.cnki.jtcm.2024.06.001.
Yang C, Wu Y, Qian J, Li J Acta Pharm Sin B. 2024; 14(10):4228-4242.
PMID: 39525586 PMC: 11544391. DOI: 10.1016/j.apsb.2024.05.011.
Wang P, Cho W, Ye D, Zhang Y, Xiong X Front Pharmacol. 2024; 15:1392930.
PMID: 38686321 PMC: 11056551. DOI: 10.3389/fphar.2024.1392930.
2023 China Guidelines for Lipid Management.
Li J, Zhao S, Zhao D, Lu G, Peng D, Liu J J Geriatr Cardiol. 2023; 20(9):621-663.
PMID: 37840633 PMC: 10568545. DOI: 10.26599/1671-5411.2023.09.008.
2023 Chinese guideline for lipid management.
Li J, Zhao S, Zhao D, Lu G, Peng D, Liu J Front Pharmacol. 2023; 14:1190934.
PMID: 37711173 PMC: 10498001. DOI: 10.3389/fphar.2023.1190934.